Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887418 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Testosterone Enanthate
A Phase 1 study, sponsored by Antares Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01887418 is a Phase 1 study that has completed, run by Antares Pharma. The registered enrollment target is 39 participants.
The verdict
NCT01887418, a Phase 1 study, has completed, sponsored by Antares Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.
Interventions
- DRUG QuickShot™ - 50 mg Treatment B
- DRUG QuickShot™ - 100 mg Treatment A
- DRUG Delatestryl 200 mg IM Treatment C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01887418
The ClinicalTrials.gov registry entry for NCT01887418 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antares Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which QuickShot™ - 50 mg Treatment B is the first listed.
NCT01887418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01887418 about?
NCT01887418 is a clinical study titled "Pharmacokinetic Study of Testosterone Enanthate". Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.
What is the current status of trial NCT01887418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2013-09. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01887418?
The interventions under investigation include: QuickShot™ - 50 mg Treatment B (DRUG), QuickShot™ - 100 mg Treatment A (DRUG), Delatestryl 200 mg IM Treatment C (DRUG).
Who is sponsoring clinical trial NCT01887418?
This trial is sponsored by Antares Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.